APGE
Price
$38.51
Change
+$1.49 (+4.02%)
Updated
Jul 10, 04:59 PM (EDT)
Capitalization
2.16B
53 days until earnings call
ERAS
Price
$1.51
Change
-$0.03 (-1.95%)
Updated
Jul 10, 04:59 PM (EDT)
Capitalization
436.26M
28 days until earnings call
Interact to see
Advertisement

APGE vs ERAS

Header iconAPGE vs ERAS Comparison
Open Charts APGE vs ERASBanner chart's image
Apogee Therapeutics
Price$38.51
Change+$1.49 (+4.02%)
Volume$46.62K
Capitalization2.16B
Erasca
Price$1.51
Change-$0.03 (-1.95%)
Volume$18.82K
Capitalization436.26M
APGE vs ERAS Comparison Chart in %
Loading...
APGE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
APGE vs. ERAS commentary
Jul 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APGE is a Hold and ERAS is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 11, 2025
Stock price -- (APGE: $37.02 vs. ERAS: $1.54)
Brand notoriety: APGE and ERAS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: APGE: 282% vs. ERAS: 110%
Market capitalization -- APGE: $2.16B vs. ERAS: $436.26M
APGE [@Biotechnology] is valued at $2.16B. ERAS’s [@Biotechnology] market capitalization is $436.26M. The market cap for tickers in the [@Biotechnology] industry ranges from $314.48B to $0. The average market capitalization across the [@Biotechnology] industry is $2.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

APGE’s FA Score shows that 0 FA rating(s) are green whileERAS’s FA Score has 1 green FA rating(s).

  • APGE’s FA Score: 0 green, 5 red.
  • ERAS’s FA Score: 1 green, 4 red.
According to our system of comparison, both APGE and ERAS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

APGE’s TA Score shows that 4 TA indicator(s) are bullish while ERAS’s TA Score has 4 bullish TA indicator(s).

  • APGE’s TA Score: 4 bullish, 5 bearish.
  • ERAS’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, both APGE and ERAS are a bad buy in the short-term.

Price Growth

APGE (@Biotechnology) experienced а -16.47% price change this week, while ERAS (@Biotechnology) price change was +6.21% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.89%. For the same industry, the average monthly price growth was +16.25%, and the average quarterly price growth was +20.89%.

Reported Earning Dates

APGE is expected to report earnings on Sep 01, 2025.

ERAS is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+9.89% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
APGE($2.16B) has a higher market cap than ERAS($436M). APGE YTD gains are higher at: -18.278 vs. ERAS (-38.645). ERAS has higher annual earnings (EBITDA): -150.24M vs. APGE (-241.42M). APGE has more cash in the bank: 513M vs. ERAS (305M). APGE has less debt than ERAS: APGE (11.8M) vs ERAS (50.8M). APGE (0) and ERAS (0) have equivalent revenues.
APGEERASAPGE / ERAS
Capitalization2.16B436M495%
EBITDA-241.42M-150.24M161%
Gain YTD-18.278-38.64547%
P/E RatioN/AN/A-
Revenue00-
Total Cash513M305M168%
Total Debt11.8M50.8M23%
TECHNICAL ANALYSIS
Technical Analysis
APGEERAS
RSI
ODDS (%)
Bearish Trend 2 days ago
69%
Bearish Trend 2 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
87%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
76%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 8 days ago
84%
Bullish Trend 2 days ago
79%
Declines
ODDS (%)
Bearish Trend 3 days ago
75%
Bearish Trend 4 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
86%
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
APGE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LKCOF0.150.09
+139.64%
Luokung Technology Corp
HIBSX104.18N/A
N/A
Hartford Stock HLS IB
GSRFX12.73N/A
N/A
Goldman Sachs Rising Dividend Gr R6
FSCNX16.27N/A
N/A
Fidelity Advisor Asset Manager 60% C
MOYFF1.28N/A
N/A
Mynaric AG

APGE and

Correlation & Price change

A.I.dvisor indicates that over the last year, APGE has been loosely correlated with SYRE. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if APGE jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APGE
1D Price
Change %
APGE100%
+1.68%
SYRE - APGE
52%
Loosely correlated
+6.02%
CRNX - APGE
51%
Loosely correlated
+10.08%
ERAS - APGE
49%
Loosely correlated
+5.48%
KRYS - APGE
49%
Loosely correlated
+3.88%
CLDX - APGE
48%
Loosely correlated
+5.30%
More

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with RVMD. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then RVMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
+5.48%
RVMD - ERAS
57%
Loosely correlated
+5.71%
LRMR - ERAS
53%
Loosely correlated
+4.22%
XNCR - ERAS
53%
Loosely correlated
+12.82%
ATXS - ERAS
52%
Loosely correlated
+5.62%
APGE - ERAS
52%
Loosely correlated
+1.68%
More